Executive Director Hematologic Cancer Research @SarahCannonDocs @SCRIOncology #Duke alum. Tweets my own, not medical advice. #cll #lymsm
Joined November 2013
- Tweets 390
- Following 324
- Followers 960
- Likes 1,204
39 Photos and videos
Krish Patel retweeted
This review article from our new Update on Antibody–Drug Conjugates supplement discusses the clinical development and current role of ADCs in the therapeutic landscape of hematologic malignancies.
acsjournals.onlinelibrary.wi…
@OncoAlert @KrishPatelMD @SAStricklandMD @SarahCannonDocs
8
9
567
Jun 2
Looking forward to a really engaging EHA and then post EHA discussion on lots of amazing new data to highlight in hematology! @SarahCannonDocs @SCRIOncology
#lymsm #heme #EHA2026 #research
REGISTER for our Post-EHA 2026 Highlights 🩸
Webinar series by VJHemOnc featuring presentations & discussions on selected abstracts from the 31st Congress of the European Hematology Association (EHA)
📍 Webinar series
🗓️ 23 June-2nd July 2026
Covering:
📌 Lymphoma - Chaired by: @KrishPatelMD
📌 MPNs - Chaired by: @harrisoncn1
📌 AML - Chaired by: @Daver_Leukemia
📌 Myeloma - Chaired by: Dr Karthik Ramasamy
📌 MDS - Chaired by: @Dr_AmerZeidan
📌 CLL - Chaired by: Dr Alexey Danilov
Agendas coming soon! 👀
Secure your spot 🔗 👉 vjhemonc.com/event/post-eha-…
4
185
Krish Patel retweeted
Wrapping up strong at #ASCO26 with SCRI Meet the Expert sessions in GI, breast, and innovation in trial delivery through Accelero. Come connect with our teams! @GHannafantastic @MeredithPelster @ErikaHamilton9 @SPremji7866
1
2
5
420
Krish Patel retweeted
Day 1 of #ASCO26 is almost here. Our experts are presenting the latest research in hematologic disorders & more.
Dr. Hans Lee will share first results from the Phase 1/2 LINKER-AL2 trial.
#SCRI #OncologyLeadership #CancerResearch
2
2
137
Krish Patel retweeted
May 26
If you are interested in lymphoma analysis from EHA2026 do sign up - should be good fun! #lymsm #lymphoma vjhemonc.com/event/post-eha-…
5
47
2,525
Krish Patel retweeted
When U.S. representation in global oncology trials falls short, access and approvals can be affected. Hans Lee MD, (SCRI) highlights the need to expand clinical trial access in community settings.
🔗 sohoinsider.com/news/when-us…
#Oncology #ClinicalTrials #CancerResearch
1
194
Krish Patel retweeted
SCRI has enrolled & treated the first patients worldwide in a first‑of‑its‑kind Phase III CAR T‑cell clinical trial for aggressive large B‑cell lymphoma—bringing innovative treatment options to patients through community‑based research. @StDavidsHC #CAR_T #Lymphoma #SCRI
1
1
198
Krish Patel retweeted
Apr 21
Come join us in Chicago May 2 for 🌟 @lymphoma Rounds 🌟
@KrishPatelMD
Chicago healthcare professionals: join us for Lymphoma Rounds as physicians share best practices and learn the latest information on advances in lymphoma treatment.
Open to currently practicing healthcare professionals ONLY.
Register here: bit.ly/3Qs1WUR
1
8
495
Feb 11
Excited to join a stellar crew of faculty in Nashville for this exciting meeting!
Excited to highlight faculty member Dr. @KrishPatelMD, Director of Lymphoma Research at Sarah Cannon Research Institute and expert medical oncologist at SCRI Oncology Partners in Nashville! With his focus on novel therapeutics, cellular therapies, and clinical trials for lymphomas and CLL, he's delivering game-changing insights to #NashvilleHeme26. FREE registration is still open for this 2-day CE-accredited conference, Feb 26-28, 2026. Secure your spot with code FREECME and join over 60 top experts: na2.hubs.ly/H03qYDn0 #Hematology #CME
9
644
Join Krish Patel, MD (@KrishPatelMD), and Nirav Shah, MD, MS (@niravshahmd), on 2/05 at 12 PM MST during #Tandem26 for a #Bcell cancers #MedEd event 🔗 bit.ly/CLL-MCLTandem26-T #HemOnc
3
7
213
Adapting to Innovation in B-Cell Cancers: Harnessing Therapeutic Advances and Revisiting HCT—join Krish Patel, MD (@KrishPatelMD), and Nirav Shah, MD, MS (@niravshahmd) on 2/05 at 12 PM MST: bit.ly/CLL-MCLTandem26-T #Tandem26 #HemOnc
3
7
208
Krish Patel retweeted
6 Oct 2025
We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI.
His legacy: 850 first-in-human trials, countless lives impacted. 💙
Welcome new leaders and read the full update: scri.com/news/scri-announces…
1
1
16
7,135
What's New in #DLBCL care?
Learn how BTK inhibitors, antibody-based therapies, and bispecifics are changing the game for frontline & relapsed/refractory disease.
Join this expert-led #MedEd program featuring Krish Patel, MD (@KrishPatelMD). #PeerView
🔗 bit.ly/4jfWkG4
3
6
221
15 Aug 2025
Fabulous talk on challenges and opportunities in trials for Cell Tx in GI Malignancies from @MeredithPelster @SarahCannonDocs #CellTx #GIOnc #SeattleCT25
1
2
19
1,084
Krish Patel retweeted
14 Aug 2025
This Friday and Saturday in Seattle! Take a look at the agenda and the list of speakers!
education.binaytara.org/cont…
Looking forward to seeing you all!
@binaytara @fredhutch #SeattleCT25
12 Aug 2025
3 DAYS TO GO! Join @mshadman and @KrishPatelMD at #SeattleCT25! Connect with leading oncologists from @fredhutch @uwmedicine @SarahCannonDocs @NebraskaMed @MDAndersonNews @ProvSwedish. Register TODAY: buff.ly/z3cKHdl #MedX #MedTwitter #leusm #lymsm #CLLsm #hemepath #ALL
7
27
4,027
Krish Patel retweeted
12 Aug 2025
3 DAYS TO GO! Join @mshadman and @KrishPatelMD at #SeattleCT25! Connect with leading oncologists from @fredhutch @uwmedicine @SarahCannonDocs @NebraskaMed @MDAndersonNews @ProvSwedish. Register TODAY: buff.ly/z3cKHdl #MedX #MedTwitter #leusm #lymsm #CLLsm #hemepath #ALL
1
7
17
4,352
Krish Patel retweeted
11 Jul 2025
Excited to share a story about the power of clinical trials! Please see our article on oncogene examining a robust and durable response with iNKT cell therapy in a patient with very refractory germ cell tumor.
@SarahCannonDocs and @SCRIOncology
nature.com/articles/s41388-0…
1
2
17
437
Krish Patel retweeted
2 Jul 2025
Can off-the-shelf iPSC-derived NK cells change the game for B-cell lymphoma?
@tix_tobi and I had the opportunity to reflect on an early-phase study by Strati et al, published in @TheLancetHaem , studying FT516—a non-CAR-bearing, iPSC-derived NK-cell Tx.
thelancet.com/journals/lanha…
1
5
12
1,542
Krish Patel retweeted
19 Jun 2025
CONGRESS | #18ICML | PRESENTATION
Krish Patel @KrishPatelMD, Sarah Cannon Research Institute, presents global phase Ib results of JNJ-90014496, a CD19/CD20 bispecific CAR T-cell therapy, in R/R LBCL (N = 48).
At the RP2D (75M cells), ORR and CRR were 95% and 80%, respectively, with no G3/4 CRS and 1 ICANS. Safety was manageable and consistent with the prior China study.
Follow our live feed for more updates: loom.ly/Pc0ysis
#Lymphoma #lymsm #MedicalCongress
4
5
803